{"id":485526,"date":"2021-05-03T07:03:46","date_gmt":"2021-05-03T11:03:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/"},"modified":"2021-05-03T07:03:46","modified_gmt":"2021-05-03T11:03:46","slug":"repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/","title":{"rendered":"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1"},"content":{"rendered":"

<\/p>\n

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1<\/b><\/p>\n

CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE<\/a>)–
\nRepare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality (SL) approach to the discovery and development of novel therapeutics, today announced the first patient has been dosed in the Company\u2019s Phase 1 clinical trial of RP-6306, a first-in-class small molecule product candidate targeting PKMYT1, which is a novel target that Repare discovered to be synthetic lethal with CCNE1 amplification and other genomic mutations to treat CCNE1-amplified, FBXW7-altered and other PKMYT1 inhibitor-sensitive cancers.\n<\/p>\n

\n\u201cThe dosing of the first patient in this RP-6306 trial marks a key milestone in Repare\u2019s development of targeted cancer therapeutics. We are pleased to have initiated this trial six months ahead of what we projected at our IPO launch last June,\u201d said Lloyd M. Segal, President and Chief Executive Officer of Repare. \u201cPatients with tumors carrying CCNE1, FBXW7 and certain other genetic alterations we have identified as sensitive to PKMYT1 inhibition have few treatment options available, and the incidence of these cancers is rising. This Phase 1 trial will assess the safety and tolerability of RP-6306, as well as dosing schedule, to inform Repare\u2019s planned Phase 2 program.\u201d\n<\/p>\n

\nThe Phase 1 multi-center clinical trial is expected to enroll approximately 70 patients with recurrent tumors characterized by specific genomic alterations predicted by Repare\u2019s SNIPRx platform to render sensitivity to RP-6306. The primary goal of the Phase 1 clinical trial is to assess preliminary safety and tolerability in patients and to establish the recommended Phase 2 dose and dosing schedule for RP-6306 for evaluation in further trials. Subject to completion and review of the Phase 1 clinical trial, the Company expects to advance RP-6306, both as monotherapy and in combination with chemotherapies and other treatment modalities, into proof-of-concept studies in 2022, targeting a variety of patient populations, including those with tumors with CCNE1 amplification, FBXW7 loss or other alterations identified through Repare\u2019s proprietary STEP2<\/sup> screens.\n<\/p>\n

About RP-6306<\/b><\/p>\n

\nRP-6306 is a first-in-class, selective, orally available inhibitor of PKMYT1 that was discovered and developed entirely in-house by Repare. Through Repare\u2019s SNIPRx screen campaign for targets that are SL with CCNE1 amplification, the Company identified and validated this novel SL gene that has the characteristics of a therapeutic target. Repare has developed novel and selective inhibitors against PKMYT1, which demonstrated compelling pre-clinical anti-tumor activity alone and in combination with certain anticancer agents, and subsequently announced the advancement of a clinical candidate to this potential, first-in-class program.\n<\/p>\n

About Repare Therapeutics, Inc.<\/b><\/p>\n

\nRepare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx\u00ae platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company\u2019s pipeline includes its lead product candidate RP-3500, a potential best-in-class ATR inhibitor currently in Phase 1\/2 clinical development, as well as RP-6306, a first-in-class, selective, oral inhibitor of PKMYT1 to treat CCNE1-amplified, FBXW7-altered and other PKMYT1 inhibitor-sensitive cancers, and a Pol\u03b8 inhibitor program. For more information, please visit reparerx.com.\n<\/p>\n

\nSNIPRx\u00ae is a registered trademark of Repare Therapeutics Inc.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are \u201cforward-looking statements. These statements may be identified by words such as \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cforecasts,\u201d \u201cgoal,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cseeks,\u201d \u201cwill\u201d and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, the clinical development of RP-6306 including the initiation, timing, design and results of the Phase 1 clinical trial of RP-6306 and the determination of a recommended Phase 2 dose; the efficacy of RP-6306 as a monotherapy or in combination with other therapies; and the ability of RP-6306 to target patient populations, including those with tumors with CCNE1 amplification, FBXW7 loss or other alterations identified through Repare\u2019s proprietary STEP2 screens. These forward-looking statements are based on the Company\u2019s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company\u2019s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including the impacts of the COVID-19 pandemic on the Company\u2019s business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause the Company\u2019s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled “Risk Factors” in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 4, 2021. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210503005361\/en\/<\/a><\/span><\/p>\n

Repare Contact:
\n<\/b>
Steve Forte
\n
Chief Financial Officer
\n
Repare Therapeutics Inc.
\n
info@reparerx.com<\/a><\/p>\n

Investors:
\n<\/b>
Argot Partners
\n
repare@argotpartners.com
\n<\/a>
212-600-1902\n<\/p>\n

Media:
\n<\/b>
David Rosen
\n
Argot Partners
\n
david.rosen@argotpartners.com
\n<\/a>
212-600-1902\n<\/p>\n

KEYWORDS:<\/b> United States North America Canada Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Genetics Clinical Trials Other Health General Health Pharmaceutical Health Science Oncology Other Science<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1 CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)– Repare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality (SL) approach to the discovery and development of novel therapeutics, today announced the first patient has been dosed in the Company\u2019s Phase 1 clinical trial of RP-6306, a first-in-class small molecule product candidate targeting PKMYT1, which is a novel target that Repare discovered to be synthetic lethal with CCNE1 amplification and other genomic mutations to treat CCNE1-amplified, FBXW7-altered and other PKMYT1 inhibitor-sensitive cancers. \u201cThe dosing of the first patient in this RP-6306 trial marks a … <\/p>\n

Continue reading “Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-485526","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRepare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1 CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)– Repare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality (SL) approach to the discovery and development of novel therapeutics, today announced the first patient has been dosed in the Company\u2019s Phase 1 clinical trial of RP-6306, a first-in-class small molecule product candidate targeting PKMYT1, which is a novel target that Repare discovered to be synthetic lethal with CCNE1 amplification and other genomic mutations to treat CCNE1-amplified, FBXW7-altered and other PKMYT1 inhibitor-sensitive cancers. \u201cThe dosing of the first patient in this RP-6306 trial marks a … Continue reading "Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-03T11:03:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210503005361r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1\",\"datePublished\":\"2021-05-03T11:03:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\\\/\"},\"wordCount\":1016,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210503005361r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\\\/\",\"name\":\"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210503005361r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-05-03T11:03:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210503005361r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210503005361r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/","og_locale":"en_US","og_type":"article","og_title":"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1 - Market Newsdesk","og_description":"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1 CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)– Repare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality (SL) approach to the discovery and development of novel therapeutics, today announced the first patient has been dosed in the Company\u2019s Phase 1 clinical trial of RP-6306, a first-in-class small molecule product candidate targeting PKMYT1, which is a novel target that Repare discovered to be synthetic lethal with CCNE1 amplification and other genomic mutations to treat CCNE1-amplified, FBXW7-altered and other PKMYT1 inhibitor-sensitive cancers. \u201cThe dosing of the first patient in this RP-6306 trial marks a … Continue reading \"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-03T11:03:46+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210503005361r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1","datePublished":"2021-05-03T11:03:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/"},"wordCount":1016,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210503005361r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/","name":"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210503005361r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-05-03T11:03:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210503005361r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210503005361r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-rp-6306-a-first-in-class-selective-oral-inhibitor-of-pkmyt1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/485526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=485526"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/485526\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=485526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=485526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=485526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}